PE Ratio
86.16
₹444.30 -37.05 (-7.70%)
As on October 30, 2026
-42.96%
1 Y CAGR
16,565
CR
Market Cap
Company profile
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
Price Chart
Fundamentals - Company Valuation
PB Ratio
0.018
Dividend Yield
1.16%
Sector PE
42.60
Sector ROE
11.70%
Sector Dividend Yield
0.46%
Financials
LIVE DATA FEED
Total Revenue (YTD)
₹22.7KCAGR 5-Year
+14.49%Peers & Comparison
SUNPHARMA
Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
DIVISLAB
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
TORNTPHARM
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Looking for AI-researched technical positive stocks?
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.
Corporate Actions
Still Thinking? Not sure which stocks are right for you?
We help investors understand what to buy, when to buy, and why it makes sense for them.
customersupport@jarvisinvest.com
New Customers (Enquiry): +91 7208809638
Mon - Sat | 10:00 AM - 07:00 PM (Sunday Closed)
